Pregabalin: Pfizer

Current Opinion in Investigational Drugs

Volumn 2, Issue 6, 2001, Pages 828-834

  Selak, I ^a  

^a UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AMITRIPTYLINE; ANTICONVULSIVE AGENT; CHOLINERGIC RECEPTOR; ETIRACETAM; GABAPENTIN; GLUTAMIC ACID; LAMOTRIGINE; LORAZEPAM; MONOAMINE; MORPHINE; OPIATE RECEPTOR; PLACEBO; PREGABALIN; TOPIRAMATE; VIGABATRIN;

ADD ON THERAPY; ANXIETY NEUROSIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIABETIC NEUROPATHY; DOSE RESPONSE; DRUG APPROVAL; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; EPILEPSY; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; HUMAN; JAPAN; MENTAL DISEASE; MONOTHERAPY; NEUROPATHY; PAIN; PANIC; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; SOCIOPATHY; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; VERTIGO;

AGORAPHOBIA; ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS; GABA AGONISTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; PAIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034799447     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Enantioselective synthesis of PD-144723: A potent stereospecific anticonvulsant
2. Measurement of a new anticonvulsant, (S)-3-(aminomethyl)-5-methylhexanoic acid, in plasma and milk by high-performance liquid chromatography
3. Neurontin CNS trials will speed development of successor product
4. Perinatal mortality in rats with the anticonvulsant CI-1008 (isobutyl-GABA)
5. Pharmacokinetics (PK) and pharmacodynamics (PD) of CI-1008 (pregabalin) and gabapentin in rats with maximal electroshock
6. Profile of the anticonvulsant activity of CI-1008 (pregabalin) in animal models
7. Pharmacokinetics of the anticonvulsant agent, CI-1008, in laboratory animals
8. New Anti-epileptic Drugs - The Fourth Eilat Conference Eilat, Israel
9. Differential effects of Gabapentin and Pregabalin on stimulation-evoked catecholamine release from rat brain slices
10. Gabapentin and S(+)-3-isobutyl-gamma-aminobutyric acid block secondary hyperalgesia
11. American Academy of Neurology - 51st Annual Meeting Focus on: Epilepsy Therapeutics, Toronto, Ontario, Canada
12. Emerging molecular approaches to pain therapy
13. Antiociceptive properties of pregabalin, a gabapentin analog in stress- and LPS-induced hyperalgesia in rats
14. W-L expects neurotin sales to reach $800 mil. and hold through 2000
15. Supraspinal and spinal mechanisms of pregabalin-induced antinociception on inflammatory colonic pain
16. Effects of pregabalin (S-(+)-3-isobutylgaba, CI-1008) on the 3,4 diaminopyridine (DAP)-induced decrease in catecholamine synthesis in the rat brain
17. Vigabatrin increases total GABA levels in rat optic nerve while gabapentin and pregabalin do not
18. Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat
19. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. A randomized controlled trial
20. Pregabalin effectively relieves pain in patients with diabetic peripheral neuropathy: Study 1008-014
21. American Diabetes Association 60th Scientific Sessions, San Antonio, TX, USA
22. FTC grants final clearance for Pfizer/Warner-Lambert merger, transaction completed today
23. New Anti-Epileptic Drugs - Fifth Eilat Conference Eilat, Israel
24. Pregabalin pharmacokinetics and safety in healthy volunteers: Results from two phase I studies
25. A double-blind, placebo-controlled trial of pregabalin for the treatment of painful diabetic neuropathy
26. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin
27. Pregabalin. Antiepileptic
28. Pregabalin in-patient monotherapy trial: A double-blind, low-dose active-controlled, multicenter study in patients with refractory partial epilepsy (protocol 1008-007)
29. Detection of static and dynamic components of mechanical allodynia in rat models of neuropathic pain: Are they signalled by distinct primary sensory neurones?
30. 3-Substituted GABA analogs with central nervous system activity: A review
31. Systemic gabapentin and S(+)-3-isobutyl-.γ.-aminobutyric acid block secondary hyperalgesia
32. Pregablin (CI-1008) single-dose pharmacokinetics and safety/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses
33. Pregabalin treatment of generalized anxiety disorder: Three randomized, placebo controlled clinical trials
34. A placebo-controlled study of pregabalin in social phobia (social anxiety disorder)
35. Merrill Lynch: Global Healthcare Bulletin
36. The effects of gabapentin in the rat hippocampus are mimicked by two structural analogs, but not by nimodipine
37. In Brief
38. Pfizer sees sustained, strong performance as broad and deep product line, new product pipeline, profit margin expansion and strategic alliances drive growth
39. American Epilepsy Society 54th Annual Meeting Los Angeles, CA, USA
40. Aiming at sales of ¥350 billion to ¥400 billion in 2005: Mr Bootes of Pfizer
41. Merrill Lynch: Global healthcare: Global healthcare bulletin
42. Pfizer restricts use of pregabalin for some clinical trial patients
43. Drug development pipeline: Pregabalin
44. Wall Street analysts meeting
45. Gabapentin and vigabatrin enhance promoted GABA release in rat hippocampus in vivo
46. Antinociceptive effect of pregabalin in septic shock-induced rectal hypersensitivity in rats
47. Pregabalin adjunctive therapy in patients with partial seizures
48. Pregabalin add-on trial: A double-blind, multi-center study in patients with partial seizures
49. Long-term safety and efficacy of pregabalin
50. Gabapentin monotherapy. I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondary generalized seizures. The US gabapentin study group 88/89
51. Treatment of social phobia with gabapentin: A placebo-controlled study
52. Safety and efficacy of standard and new antiepileptic drugs
53. Metabolic disposition of pregablin in healthy volunteers
54. Mixed effects modeling of pregablin response in patients with refractory partial seizures
55. Pharmaceuticals: First quarter preview